Compare Booz Allen Hamilton Holding Corporation (BAH) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Booz Allen Hamilton Holding Corporation vs BioNTech SE - ADR — how do they compare? Booz Allen Hamilton Holding Corporation trades at $78.09 (market cap $9.45B), while BioNTech SE - ADR trades at $93.06 (market cap $23.31B). The key difference: BioNTech SE - ADR is far larger — about 2.5× Booz Allen Hamilton Holding Corporation's market cap, and Booz Allen Hamilton Holding Corporation pays a 3% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BAH | BNTX | |
|---|---|---|
Market Cap | $9.45B | $23.31B |
Sector | Industrials | Health |
52-Week High | $111.63 | $119.34 |
52-Week Low | $59.71 | $83.89 |
Enterprise Value | $13.07B | $6.60B |
Dividend Yield | 3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Booz Allen Hamilton (BAH) trades at $77.93, up 0.04% on the day, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a 7.01% net margin and 68.11% ROE, while valuation ratios like P/E of 12.33 and P/S of 0.86 appear attractive. Recent Q2 2026 earnings beat estimates at $1.81 per share, and the company maintains consistent dividend payments, reflecting financial stability.
Outlook remains positive with analyst consensus price target of $84.67, though risks include high debt levels and civil revenue weakness. Growth in national security and AI investments offers upside, but investors should monitor leverage and sector-specific headwinds for balanced exposure.
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
